Carbapenems are considered as last-resort antibiotics for the treatment of infections caused
by multidrug-resistant Gram-negative bacteria. With the increasing use of carbapenems in …

Therapy of invasive infections due to multidrug-resistant Enterobacteriaceae (MDR-E) is
challenging, and some of the few active drugs are not available in many countries. For …

Necrotizing Soft-Tissue Infections | New England Journal of Medicine Skip to main content
Access provided byUT MD ANDERSON CANCER CENTER The New England Journal of …

Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic
boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam …

Ceftazidime-avibactam was used to treat 77 patients with carbapenem-resistant
Enterobacteriaceae (CRE) infections at our center. Thirty-and 90-day survival rates were …

Introduction A systematic literature review was undertaken to evaluate real-world use of
ceftazidime-avibactam for infections due to aerobic Gram-negative organisms in adults with …

Background Rates of colonization and infection with carbapenem-resistant Gram-negative
pathogens are on the rise, particularly in southeastern European countries, and this is …

Abstract Background Carbapenem-resistant Enterobacteriaceae (CRE) represent an
important global threat. The aim of this study is to describe the clinical course and outcomes …

Clinicians may use ceftazidime/avibactam in combination with other active agents to treat
infections due to carbapenem-resistant organisms, although no conclusive data support this …

The in vitro activities of ceftazidime-avibactam and comparators against 9,149 isolates of
Enterobacteriaceae and 2,038 isolates of Pseudomonas aeruginosa collected by 42 …